Novateor Research Laboratories cites SME exemption for related party disclosures
- Novateor Research Laboratories notified BSE that related party disclosures are not applicable for H1FY26
- The exemption stems from the company's listing on the BSE SME Platform under SEBI Regulation 15(2)
- Filing dated October 15, 2026, references Regulation 23(9) of SEBI LODR Regulations, 2015

*this image is generated using AI for illustrative purposes only.
Novateor Research Laboratories Limited stated that submission of related party disclosures is not applicable for the half year ended September 30, 2026. The company cited its listing on the BSE SME Platform as the basis for this exemption under SEBI regulations.
The company filed a letter with the Department of Corporate Services at BSE Limited on October 15, 2026. The communication referenced Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which typically mandates such disclosures for listed entities.
Regulatory basis for exemption
Novateor invoked Regulation 15(2) of the SEBI LODR Regulations, 2015. This provision specifies that certain compliance requirements do not apply to entities listed on the SME Exchange. The exempted regulations include:
- Regulation 17, 17A, 18, 19, 20, 21, 22, 23, 24, 24A, 25, 26, and 27
- Clause (b) to (i) and (t) of sub-regulation (2) of Regulation 46
- Para C, D, and E of Schedule V
Consequently, the company asserted that compliance with Regulation 23(9) regarding related party transactions is not required for the specified period.
Corporate details
The filing was signed by Navdeep Subhashbhai Mehta, Managing Director of Novateor Research Laboratories. The company’s registered office is located in Sanand, Gujarat. The letter requested BSE to take the non-applicability status on record.
Historical Stock Returns for Novateor Research Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
How might the exemption from related party transaction disclosures impact investor confidence and valuation multiples for Novateor Research Laboratories?
Are there plans for Novateor to migrate from the BSE SME Platform to the main board, which would trigger stricter disclosure requirements?
What is the current volume and nature of related party transactions for Novateor, given the lack of mandatory public reporting?


































